10价与13价肺炎球菌结合疫苗对儿童肺炎住院的影响:系统综述与Meta分析
该系统综述与Meta分析纳入12篇时间序列分析和前后对照研究,评估PCV10和PCV13引入免疫规划后对5岁以下儿童肺炎住院率的影响。结果显示,<24月龄儿童中临床诊断和影像学确诊肺炎住院率分别降低17%和31%,24-59月龄分别降低9%和24%。作者认为需进一步设计良好的研究比较PCV10与PCV13的影响。
要点
- PCV10/PCV13引入后,<24月龄儿童临床诊断肺炎住院率降低17%(95%CI:11-22%)。
- PCV10/PCV13引入后,<24月龄儿童影像学确诊肺炎住院率降低31%(95%CI:26-35%)。
- 24-59月龄儿童临床诊断和影像学确诊肺炎住院率分别降低9%和24%。
核心结论
- PCV10和PCV13对减少肺炎住院率有显著影响,尤其在<24月龄儿童和影像学确诊肺炎中更为明显。
- 需要进一步设计良好的研究比较PCV10和PCV13的影响,以获得制定未来免疫策略的可靠数据。
研究设计与样本
- 系统综述与Meta分析,检索并纳入时间序列分析和前后对照研究,报告引入PCV10或PCV13到免疫规划前后肺炎住院发病率。
- 共识别1533篇可能相关文章,最终纳入12篇分析。
主要发现
- 在<24月龄儿童中,引入新型PCVs后,临床诊断肺炎住院率降低17%(95%CI:11-22%,p值<0.001),影像学确诊肺炎住院率降低31%(95%CI:26-35%,p值<0.001)。
- 在24-59月龄儿童中,引入新型PCVs后,临床诊断肺炎住院率降低9%(95%CI:5-14%,p值<0.001),影像学确诊肺炎住院率降低24%(95%CI:12-33%,p值<0.001)。
- 评估临床诊断和影像学确诊肺炎住院率的研究间存在高度异质性。
关键数值与推荐
- 纳入标准:时间序列分析或前后对照研究,报告PCV10或PCV13引入免疫规划前后肺炎住院发病率。
- 按年龄组(<24月龄和24-59月龄)和肺炎病例定义(临床诊断和影像学确诊)进行分层分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 评估临床诊断和影像学确诊肺炎住院率的研究间存在高度异质性。
- 需要进一步设计良好的研究比较PCV10和PCV13的影响,以获得制定未来免疫策略的可靠数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This systematic review and meta-analysis aimed at summarizing available data on the impact of PCV10 and PCV13 in reducing the incidence of CAP hospitalizations in children aged <5years. METHODS: A systematic search of the literature was conducted. We included time-series analyses and before-after studies, reporting the incidence of hospitalization for pneumonia in the periods before and after the introduction of PCV10 or PCV13 into the immunization program. Pooled estimates of Incidence Rate Ratio (IRR) were calculated by using a random-effects meta-analytic model. Results were stratified according to age-groups (<24months and 24-59months) and case definitions of pneumonia (clinically and radiologically confirmed pneumonia). RESULTS: A total of 1533 potentially relevant articles were identified. Of these, 12 articles were included in the analysis. In children aged <24months, the meta-analysis showed a reduction of 17% (95%CI: 11-22%, p-value<0.001) an of 31% (95%CI: 26-35%, p-value<0.001) in the hospitalization rates respectively for clinically and radiologically confirmed pneumonia, respectively, after the introduction of the novel PCVs. In children aged 24-59months, the meta-analysis showed a reduction of 9% (95%CI: 5-14%, p-value<0.001) and of 24% (95%CI: 12-33%, p-value<0.001) in the hospitalization rates for clinically and radiologically confirmed pneumonia, respectively, after the introduction of the novel PCVs. High heterogeneity was detected among studies evaluating the hospitalization rate for clinically and radiologically confirmed pneumonia. CONCLUSIONS: The results of this study revealed a significant impact of PCV10 and PCV13 in reducing the hospitalizations for pneumonia, particularly in children aged <24months and for radiologically confirmed disease. Further appropriately designed studies, comparing the impact of PCV10 and PCV13, are needed in order to obtain solid data on which to establish future immunization strategies.
引用
- Alicino C, Paganino C, Orsi A, et al. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: A systematic review and meta-analysis. Vaccine. 2017. PMID: 28911902. doi:10.1016/j.vaccine.2017.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。